Fintel reports that on February 24, 2025, JP Morgan upgraded their outlook for bluebird bio (NasdaqGS:BLUE) from Underweight to Neutral. Analyst Price Forecast Suggests 807.14% Upside As of February ...

In a report released on March 10, Anupam Rama from J.P. Morgan maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a ...

Fintel reports that on February 24, 2025, JP Morgan upgraded their outlook for bluebird bio (LSE:0HOH) from Underweight to Neutral. As of January 28, 2025, the average one-year price target for ...

In a report released on March 6, Anupam Rama from J.P. Morgan maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a ...

J.P. Morgan Funds is committed to providing the highest level of global insights, investment solutions and service support to strengthen and grow client relationships. https://www.jpmorganfunds ...